BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).

NCT03227263 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Rendu Osler Disease
Telangiectasia, Hereditary Hemorrhagic

Interventions

DRUG: Bevacizumab
DRUG: sodium chloride 0.9%

Sponsor

Hospices Civils de Lyon